, Columnist
Express Scripts, the Good Guy on Drug Prices? Not Exactly
Its efforts to lower drug prices likely won't change much, and it probably knows that.
The biggest victor in all this may be Express Scripts’ public relations department.
Photographer: Whitney Curtis/Getty Images
This article is for subscribers only.
Express Scripts Holding Co. is trying to lay low as regulators scrutinize Cigna Inc.’s plan to purchase the company. After releasing first quarter earnings Wednesday afternoon, it didn’t even host a conference call.
That’s not to say it hasn’t been active. The pharmacy benefit manager (PBM) last week proposed a radical pricing shift for a new set of migraine medicines. And on Tuesday, it announced a deal with Sanofi and Regeneron Pharmaceuticals Inc. that will slash the price of a cholesterol drug.